Citation Information :
Soydal C, Araz M, Kucuk ON, Ozkan E, Demirer T. Recurrent Medullary Carcinoma detected by Gallium-68 Positron Emission Tomography. World J Endoc Surg 2013; 5 (2):59-60.
Soydal C, Ozkan E, Araz M, Kucuk ON, Demirer T. Recurrent Medullary Carcinoma detected by Gallium-68 Positron Emission Tomography. World J Endoc Surg 2013;5(2):59-60.
Medullary thyroid cancer: management guidelines of the American Thyroid Association. American Thyroid Association Guidelines Task Force, Thyroid. 2009 Jun;19(6):565-612.
Medullary thyroid cancer. Nuclear medicine in clinical diagnosis and treatment. 3rd ed. London: Churchill Livingstone; 2004;P165-174.
18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001 Jan;28(1):64-71.
The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000 May;27(5):490-496.
Impact of 18F-fluoro-2- deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004 Aug;11(8):786-794.
The role of PETCT scan with somatostatin analogue labelled with gallium-68 (68Ga-DOTATATE PETCT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Endokrynol Pol 2010 Sep-Oct;61(5):507-511.
Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. QJ Nucl Med Mol Imaging 2010 Feb;54(1):52-60.
